NeuroPace Inc (NPCE) NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Sector: Surgical & Medical Instruments & Apparatus
Industry: Medical - Devices
NeuroPace, Inc. NASDAQ:NPCE Healthcare · Medical - Devices
Mkt Cap $422.19M
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release
NeuroPace to Report Third Quarter 2026 Financial Results on November 12, 2026
NeuroPace announced it will report third quarter 2026 financial results after market close on Thursday, November 12, 2026.
Management will host a conference call at 1:30 p.m. Pacific Time, with a live webcast available on the company's investor relations site and an archive replay for at least 90 days.
The release contains no financial results or guidance; it is purely an earnings-date notice.
• 3d ago AI analysis › Press Release
NeuroPace to Participate in 2026 Cantor Global Healthcare Conference
NeuroPace announced that management will participate in the upcoming 2026 Cantor Global Healthcare Conference.
The company is scheduled for a fireside chat on September 9 at 10:55 a.m. EDT and will host one-on-one meetings with investors.
The fireside chat will be accessible via live webcast, with a replay available on the NeuroPace investor website.
• 2mo ago AI analysis › Press Release
NeuroPace to Participate in Wells Fargo 21st Annual Healthcare Conference
NeuroPace management is scheduled to attend the Wells Fargo 21st Annual Healthcare Conference.
The team will participate in a fireside chat on September 8 at 8:00am ET, accessible via live webcast, and conduct one-on-one investor meetings.
A replay of the fireside chat will be available on the company's investor relations website.
• 2mo ago AI analysis › Press Release ● Critical ⚠ 1
NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance
NeuroPace reported Q2 total revenue of $22.8 million, up 17% year-over-year, driven by a 21.3% increase in RNS System revenue to $22.5 million.
The company raised its full-year 2026 revenue guidance to $99.5 million to $101.5 million, reflecting 21% to 23% growth in core RNS revenue, and improved its adjusted EBITDA guidance range by $1 million.
Operational highlights included the launch of the ECoG Assistant AI tool and progress toward the FDA meeting for the IGE indication expansion, supported by positive NAUTILUS trial data.
• 2mo ago AI analysis › Press Release ● Critical ⚠ 3
NeuroPace Receives FDA Guidance on PMA Supplement for Indication Expansion into Idiopathic Generalized Epilepsy
NeuroPace announced that the FDA has determined its PMA Supplement for idiopathic generalized epilepsy is not approvable in its current form, requesting additional clinical evidence from the NAUTILUS trial.
Management plans to submit a Submission Issue Request to discuss the agency's feedback and intends to amend the submission with the requested supplemental data.
The NAUTILUS study previously showed a 77% median reduction in GTC seizures at 18 months and 100% reduction in a subset at 24 months, but the FDA determined this was insufficient for approval at this time.
• 3mo ago AI analysis › Press Release
NeuroPace to Highlight Expanding Role of Responsive Neuromodulation at the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting
NeuroPace will participate in the 2026 ASSFN Meeting in Cleveland, Ohio, from May 29 to June 2, 2026.
The company will host a symposium on thalamic neuromodulation and NAUTILUS data in idiopathic generalized epilepsy, presented by CMO Martha Morrell.
NeuroPace will also showcase its recently FDA-approved ECoG Assistant AI tool and gather physician feedback on the RNS System at its booth.
• 5mo ago AI analysis › Press Release ● Major
NeuroPace Announces FDA Approval of ECoG Assistant™, Advancing AI-Driven Epilepsy Care
NeuroPace announced FDA approval of ECoG Assistant, its first AI-driven clinician-enabled feature for the RNS System.
The tool leverages a dataset of 124,450 labeled intracranial EEG records to help physicians identify ECoGs of Interest and review trends more efficiently.
The company plans to debut the technology at the ASSFN Annual Meeting on May 30, 2026, and has also submitted its next-generation cloud-based Patient Data Management System for FDA review, expecting approval in Q2 2026.
• 5mo ago AI analysis › Press Release
NeuroPace to Report First Quarter 2026 Financial Results on May 12, 2026
NeuroPace announced it will report its first quarter 2026 financial results after the market close on Tuesday, May 12, 2026.
Management will host a corresponding conference call and webcast at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).
The call can be accessed via webcast or telephone, and a replay will be archived on the company's investor relations website for at least 90 days.
• 6mo ago AI analysis › Press Release
NeuroPace Highlights Expanding Clinical Evidence Leadership with Published 3-Year Post-Approval Study (PAS) Results in Neurology and NAUTILUS Presentation at AAN 2026
NeuroPace announced the publication of 3-year results from its Post-Approval Study in Neurology, showing an 82% median seizure reduction in drug-resistant focal epilepsy among 324 patients.
The company also presented 12- and 18-month data from its NAUTILUS trial at AAN 2026, demonstrating a 77% median reduction in generalized tonic-clonic seizures and significant safety improvements for idiopathic generalized epilepsy.
Management emphasized that the growing body of clinical evidence reinforces the RNS System’s differentiated position across both focal and generalized epilepsy populations.
• 6mo ago AI analysis › 
